Decoy Therapeutics Inc.
DCOY
$5.15
-$0.29-5.33%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -31.78% | 12.66% | -0.25% | 0.44% | -4.49% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -34.30% | 6.74% | -15.76% | -33.14% | -51.65% |
| Operating Income | 34.30% | -6.74% | 15.76% | 33.14% | 51.65% |
| Income Before Tax | -124.52% | -0.22% | 21.05% | 37.54% | 55.55% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -124.52% | -0.22% | 21.05% | 37.54% | 55.55% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -124.52% | -0.22% | 21.05% | 37.54% | 55.55% |
| EBIT | 34.30% | -6.74% | 15.76% | 33.14% | 51.65% |
| EBITDA | 34.37% | -6.75% | 15.71% | 33.12% | 51.65% |
| EPS Basic | -712.14% | -- | -- | -- | -- |
| Normalized Basic EPS | 80.45% | -- | -- | -- | -- |
| EPS Diluted | -712.14% | -- | -- | -- | -- |
| Normalized Diluted EPS | 80.45% | -- | -- | -- | -- |
| Average Basic Shares Outstanding | 19.74% | -- | -- | -- | -- |
| Average Diluted Shares Outstanding | 319.74% | -- | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |